Different requirements around choice of comparators, relevant outcomes, quality of life, and patient populations make developing a robust evidence generation plan challenging.

And yet it’s critical for pharmaceutical and biotech companies planning future EU commercialisation.

Early dialogue can help.

But sequencing and managing the different potential routes to integrated advice, and then being organisationally nimble to implement the recommendations (or to understand the trade-offs) is a challenge.

Core Deliverables
  • Landscape analysis
  • Global–UK evidence planning workshops
  • Early scientific advice strategy
  • Early scientific advice briefing books
  • PIM/EAMS applications
  • ILAP support

  • Landscape analysis
  • Global–UK evidence planning workshops
  • Early scientific advice strategy
  • Early scientific advice briefing books
  • PIM/EAMS applications
  • ILAP support

Better teams, not bigger teams

We’ve joined forces with other experts in our network to make this process effective and efficient, particularly for small-mid size organisations who may need to balance internal resource constraints against the need for external advice.

Meet our Partners

Optimal evidence generation planning

From a UK perspective, we can help you identify and mitigate potential barriers to successful HTA, and support in developing a robust evidence generation roadmap. Typically conducted when – or just after – the registration clinical trial protocol is locked down, our asset handover workshops bring together Global and UK colleagues to plan for successful HTA in 2-3 years’ time.

Taking complexity and making it simple isn’t easy. Let us help you smooth the pathway to launch success.

See our HTA capabilities

“I think it’s fair to say that the number of questions asked really reflects the quality of the briefing book we submitted – really well done guys.”

UK Market Access Manager, Top 20 pharma

Related Case Studies

Collaboration|HTA

Cross-company collaboration on a NICE HTA


Seamless collaboration with Delta Hat to deliver NICE & SMC submissions under tight timelines…

Read more from Cross-company collaboration on a NICE HTA

Early Dialogue

HTA scientific advice for a cell therapy in lymphoma


Supporting Global and UK pharma with early dialogue in the UK and France…

Read more from HTA scientific advice for a cell therapy in lymphoma